Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alexion Eyes Soliris' Japan Launch, Analysts Upbeat About Pricing And Market Size

This article was originally published in PharmAsia News

Executive Summary

Japan's Ministry of Health, Labor and Welfare recently approved Alexion Pharmaceutical's Soliris (eculizumab) for the rare blood disorder paroxysmal nocturnal hemoglobinuria, and analysts believe it may beat initial expectations once it hits the market

You may also be interested in...



Alexion Prepares To Launch Soliris In Japan Following Record NHI Price Listing Time

Japan's Central Social Medical Insurance Agency (Chuikyo) approved Soliris (eculizumab) National Health Insurance price listing at its June meeting, three months ahead of a previously estimated fall listing, and Soliris maker Alexion Pharmaceutical is gearing up for an earlier launch in Japan

Alexion Prepares To Launch Soliris In Japan Following Record NHI Price Listing Time

Japan's Central Social Medical Insurance Agency (Chuikyo) approved Soliris (eculizumab) National Health Insurance price listing at its June meeting, three months ahead of a previously estimated fall listing, and Soliris maker Alexion Pharmaceutical is gearing up for an earlier launch in Japan

Japan Adds 12 Drugs To NHI Price List; Takeda Takes Four, Pfizer, Alexion Also Gain

Japan's Central Social Medical Insurance Agency (Chuikyo) June 2 approved the addition of 29 products of 12 ingredients. Among them, six are new chemical entities, four are new combinations and two are new administration routes with one additional indication and dosage

UsernamePublicRestriction

Register

WI964856

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel